BackSunshine Biopharma- Warrants (15/02/2027) Overview

Sunshine Biopharma- Warrants (15/02/2027) Current Assets

Sunshine Biopharma- Warrants (15/02/2027)'s current assets is $25M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$24.78M
1.23% YoYΔ $302196.00 vs prior year quarter

Peer average

Loading

Sunshine Biopharma- Warrants (15/02/2027) Current Assets History

Loading

Sunshine Biopharma- Warrants (15/02/2027) vs. peers: Current Assets Comparison

Loading

Sunshine Biopharma- Warrants (15/02/2027) Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sunshine Biopharma- Warrants (15/02/2027) (SBFMW) FAQ

As of the most recent data (March 2026), SBFMW shows a current assets of $25M. That compares with $24M in the prior-year period — up 1.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBFMW's current assets is now $25M (was $24M) — a 1.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sunshine Biopharma- Warrants (15/02/2027) is outperforming or lagging.

Tracking SBFMW's current assets over time shows whether Sunshine Biopharma- Warrants (15/02/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $25M That compares with $24M in the prior-year period — up 1.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Sunshine Biopharma- Warrants (15/02/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $25M) with ownership activity and broader fundamentals.

Sunshine Biopharma- Warrants (15/02/2027)'s current assets is $25M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.